Pennsylvania Clinical Trials Report — June 2026

For Pennsylvanians considering participation in clinical research, June 2026 presents both urgent deadlines and exciting new opportunities. A significant number of studies are nearing their enrollment goals, with 226 clinical trials statewide slated to close within the next 90 days. This includes 50 studies actively seeking healthy volunteers, offering a critical window for those without specific health conditions to contribute to medical advancements.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers, chronic pain, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Cancer (6 trials)
• Breast cancer (4 trials)
• Chronic pain (4 trials)
• Stroke (4 trials)
• Osteoarthritis (3 trials)
• Advanced solid tumor (3 trials)
• Prostate cancer (3 trials)
• HIV infections (3 trials)
• Cardiovascular diseases (3 trials)
• Endometriosis (3 trials)

Major Research Initiatives Launch Across Pennsylvania

This month, Pennsylvania welcomes 62 new clinical trials, matching the number of studies that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• Pfizer is leading an important Phase 3 vaccine trial, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• For those with obesity or overweight and Type 2 Diabetes Mellitus, Gasherbrum Bio, Inc. is also sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3 study will enroll 1,100 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• The University of Pennsylvania is sponsoring two large-scale studies focused on preventive health. NCT07636187, "Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters," aims to enroll 16,416 participants to improve engagement with preventive health services. Similarly, NCT07636174, "Colorectal Cancer Screening Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters," seeks 3,888 participants to address barriers to colorectal cancer screening.
• Another notable study is NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," sponsored by RTI International. This long-term study aims to enroll 1,400 participants of all ages to better understand the health, development, and everyday experiences of people with Down syndrome.

New Research Opportunities Across Conditions and Interventions

The 62 new trials opening this month in Pennsylvania cover a diverse range of health conditions, with a strong focus on metabolic health, chronic conditions, and cancer prevention. The most common conditions addressed by these new studies include:

• Obesity (5 trials)
• Overweight (3 trials)
• Chronic pain (2 trials)
• Diabetes mellitus, type 2 (2 trials)
• Head and neck cancer (2 trials)
• Behavior, health (2 trials)
• Chronic weight management (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 29 of the new studies. Behavioral interventions are also well-represented with 13 new trials, alongside device studies (11 trials), biological treatments (3 trials), and diagnostic tests (2 trials).

Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Pennsylvania sponsoring 7 of the new trials. Industry sponsors are also driving significant research efforts, with 26 new trials sponsored by pharmaceutical companies such as Novo Nordisk A/S, Eli Lilly and Company, Gasherbrum Bio, Inc., AstraZeneca, and Kallyope Inc.

Pennsylvania's Research Footprint: Geographic Accessibility

Pennsylvania's clinical research landscape is robust, with 3,187 clinical trials currently recruiting across 168 cities and 1,697 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's major metropolitan areas, ensuring broad access for many residents. The cities with the most new trials include:

• Philadelphia (27 new trials)
• Pittsburgh (22 new trials)
• Allentown (3 new trials)
• Smithfield (3 new trials)
• Erie (2 new trials)
• Duncansville (2 new trials)
• Bethlehem (2 new trials)
• Scottdale (2 new trials)

Beyond these major hubs, new opportunities are also available in Newport and Uniontown, demonstrating a continued effort to spread research access across different regions of the state.

Who Can Participate? Eligibility and Inclusivity

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 62 new trials launched this month, 13 are actively seeking healthy volunteers. Statewide, a total of 369 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Pennsylvania are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 13 include children as participants, and 51 include older adults, ensuring that research benefits diverse age groups. Additionally, 4 new trials are specifically designed for female-only participants.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Pennsylvania.